Pelekanou, Vasiliki http://orcid.org/0000-0002-8431-1927
Villarroel-Espindola, Franz
Schalper, Kurt A.
Pusztai, Lajos
Rimm, David L.
Funding for this research was provided by:
Breast Cancer Research Foundation (not applicable, not applicable)
Susan G. Komen for the Cure
National Cancer Institute (P30CA016359, P50CA196530)
Article History
Received: 30 July 2018
Accepted: 7 November 2018
First Online: 17 December 2018
Ethics approval and consent to participate
: This retrospective research and tissue collection was reviewed and approved by Yale Human Investigation Committee protocol #9505008219 or #1010007459 (or both) prior to collection. The Yale Human Investigation Committee approved the patient consent forms (including publication of research data) or, in some cases, a waiver of consent. Images from tissue specimens are entirely unidentifiable and no details on individuals are reported within the manuscript.
: The consent for publication of research data was included in the consent forms and approved by the Yale Human Investigation Committee.
: DLR has served as an advisor for AstraZeneca, Agendia, Bristol-Myers Squibb, Cell Signaling Technology, Genoptix/Novartis, Merck, and PerkinElmer. LP receives research funding from and served as consultant for Merck. KAS has served as an advisor for Celgene and Shattuck Labs and receives funding from Navigate Biopharma, Tesaro, Takeda, Onkaido Therapeutics, and Surface Oncology. VP is currently an employee of Sanofi. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.